Nordic Nanovector, an Oslo, Norway-based biopharmaceutical company focused on antibody radionuclide conjugates, has formed a collaboration with LegoChem Biosciences, a Daejeon, South Korea-based biopharmaceutical company, to develop CD37-targeting antibody-drug conjugates for the treatment of leukemia. This collaboration supports Nordic Nanovector’s strategy to expand its pipeline of targeted therapies to include CD37-targeting antibody products conjugated to anti-cancer compounds that are not radionuclides.

Source: Nordic Nanovector